Skip to content
Nobel Jews
Portrait of Paul Ehrlich
Photo: Eduard Blum, https://wellcomeimages.org/indexplus/image/M0013322.html · CC BY 4.0 via Wikimedia Commons

Nobel Prize in Physiology or Medicine · 1908

Paul Ehrlich

He dreamed of 'magic bullets' that kill germs but spare the patient; his lab built one: Salvarsan, the first effective syphilis drug.

The Nobel citation: “in recognition of their work on immunity”
Born
March 14, 1854, Strehlen, Prussia (now Strzelin, Poland)
Died
August 20, 1915, Bad Homburg vor der Höhe, Germany
Shared with
Ilya Mechnikov
Affiliation at the time
Goettingen University, Germany; Königliches Institut für experimentelle Therapie (Royal Institute for Experimental Therapy), Germany

Medicine prize

1908

Shared with 1 other laureate.

Age that year

54years

Born in 1854.

Headline credited impact

225,000–372,000lives saved

TB deaths averted by treatment, credited via the acid-fast stain used to find patients. How it was built

Sources cited

28

Fact-checked September 24, 2026.

  • He coined the terms 'chemotherapy' and 'magic bullet' for drugs that seek out a germ and leave the patient's own cells alone.
  • Salvarsan was compound 606 in his lab's series. It had been shelved as useless until his colleague Sahachiro Hata retested it in 1909.
  • Before Salvarsan went on general sale, his institute gave doctors about 65,000 doses free; by the end of 1910 more than 20,000 patients had been treated.
  • As a student and young doctor he used dyes to tell blood cells apart, and he named two kinds of immune cell: mast cells and eosinophils.
  • The Nazis stripped his name from a Frankfurt street because he was Jewish, and a 1935 appointee at his former institute had all his writings removed from its library.

The breakthrough

Magic bullets: Salvarsan, the first effective drug against syphilis (1909-1910)

As a medical student, Ehrlich noticed something about the new synthetic dyes: each one stained some cells and ignored others. Dyes, it seemed, could pick their targets. He spent his career asking whether medicines could do the same, clinging to a germ while leaving the patient's own cells alone. He called such drugs 'magic bullets' and named the whole approach chemotherapy. First he helped tame diphtheria. The new antitoxin serum worked, but batches varied so much in strength that doses were guesswork. Ehrlich invented a reliable way to measure each batch against a fixed standard unit, so doctors could trust the dose. That work, and his theory of how the body makes antibodies, earned him a share of the 1908 Nobel Prize. He then hunted for a chemical cure. His team made hundreds of arsenic compounds, changing small parts of the molecule each time, and tested every one on infected animals. Think of a locksmith cutting key after key until one fits the lock. Compound number 606 had been set aside as useless, but in 1909 his colleague Sahachiro Hata retested it on rabbits infected with syphilis and found that it cleared the infection. Launched in 1910 as Salvarsan, it was the first effective drug for syphilis. It also set the pattern for modern drug discovery: make many related molecules, screen them systematically, then test the best one carefully in patients.[2],[5],[6],[7],[8],[10],[12]

“magic bullets which seek their target of their own accord”
Paul Ehrlich, From his address at the opening of the Georg-Speyer-Haus research institute in Frankfurt, September 1906, describing the drugs he hoped chemists would create (English translation quoted in the Dictionary of Scientific Biography).[5]

What it meant for humanity

Before 1910, syphilis was common, disfiguring and often deadly, and the standard remedy, mercury, was so toxic that it killed some of the patients it was meant to help. Years after infection the disease could attack the heart, brain and nerves, and mothers passed it to their babies. In the early 1930s, US health surveys estimated that about one American in ten was infected. Salvarsan and its easier successor, Neosalvarsan (1912), were the first drugs that reliably killed the syphilis germ inside the body. One early doctor reported that sores healed so fast that after a few days there was nothing left to show. Demand was overwhelming: by the end of 1910 about 65,000 doses had gone to more than 20,000 patients, and by 1923 the United States alone made about 2 million doses a year. Arsenic drugs, later combined with bismuth, stayed the main treatment for syphilis until penicillin arrived in the 1940s. For early syphilis, success rates above 90% were reported among patients who finished the long course, though many did not finish. Ehrlich's other gifts lasted too. His standard unit for antitoxin let serum institutes around the world check that diphtheria serum was strong enough, an early model for testing the potency of biological medicines. The institute that grew from his serum-testing lab, now the Paul-Ehrlich-Institut, is Germany's federal agency for vaccines and biomedicines. His dye methods let doctors tell blood cells apart and diagnose leukemias and anemias, and his stain for the tuberculosis germ led to tests still used today.

  • By the end of 1910, about 65,000 doses of Salvarsan had been given to more than 20,000 patients, a test series without precedent for a drug not yet on the market.[7]
  • By 1923 the United States alone was producing about 2 million doses a year of arsphenamine (Salvarsan) and its more soluble successor, neoarsphenamine.[11]
  • In the early 1930s, when surveys suggested about one American in ten had syphilis, arsenic drugs descended from Salvarsan, usually with bismuth, were the mainstay of treatment until penicillin arrived in 1943.[14],[18]
  • His method of measuring diphtheria antitoxin against a fixed standard unit was widely adopted: serum-testing agencies abroad took up the German system and used reference serum supplied from Frankfurt.[5],[12]
  • Later scientists adapted his 1882 stain for the tuberculosis germ into the Ziehl-Neelsen stain, which labs still use, and his method also fed into the Gram stain for bacteria.[2]
  • In his 1908 Nobel lecture he described breeding parasite strains that resisted particular drugs, one of the first demonstrations that microbes can acquire drug resistance.[3],[6]

Impact in numbers

Ehrlich's clearest measurable legacy is Salvarsan and the arsenic drugs that followed it, the main treatment for syphilis for more than 30 years. No one has published a count of the lives it saved, and deaths averted would be hard to separate from other causes, so we record only a rough, low-confidence estimate of how many people were treated, credited 40% to Ehrlich. We put no numbers on his other contributions, though they may matter as much: the standard unit that made diphtheria antitoxin doses reliable, the staining methods behind blood-cell diagnosis and the tuberculosis stain, the idea of cell 'receptors' that grew from his side-chain theory, and his discovery that microbes can become resistant to drugs. Above all, he created the method of modern drug discovery: make many related compounds, screen them in animals, then test the best candidate carefully in patients. Later antibiotics and targeted medicines follow that path, but crediting them to him with a number would not be honest.

HealthFundamental science

Each number is the laureate’s credited share of a real-world outcome, cumulative to 2025. The whole outcome, the share of credit, and the reasoning are shown so you can check the arithmetic. Outcomes shared with other laureates are counted once on the impact page.

  • Low confidenceDirectModeledHealth

    People treated for syphilis with Salvarsan and related arsenic drugs, 1910 to the penicillin era

    2–8

    million people benefited, credited share

    That is 40% of 5–20 million people benefited since 1910.

    How this number was built

    No published total exists; this is a rough model. By 1923 the US alone made about 2 million arsenical doses a year (C&EN) and had about 500,000 new infections a year in the 1930s (Englund). A full course needed about 20 arsenic injections (Bosch and Rosich), but perhaps a quarter of patients finished (Willcox, via AI Impacts), so we assume 6-15 doses per patient: 130,000-330,000 US patients a year. For 1911-1945, allowing slow uptake in the 1910s, we use 100,000-250,000 a year: 3.5-8.75 million. Arsenicals were standard across Europe and beyond (Williams), so we add 0.5-1.5 times the US total for the rest of the world: 5.25M (rounded to 5M) and 21.9M (rounded down to 20M). Share 0.4: Ehrlich conceived and led the search; Hata, Bertheim, Hoechst and later arsenical makers share the rest.[6],[7],[11],[14],[15],[16]

    Sources: James Lind Library; Chemical & Engineering News (American Chemical Society); Journal of Military and Veterans' Health; Cleveland Clinic Journal of Medicine; AI Impacts; Karger, via PubMed Central

  • Low confidenceDirectModeledHealth

    Diphtheria deaths, mostly of children, averted by antitoxin serum in Germany and the US

    15,200–57,600

    lives saved, credited share

    That is 8% of 190,000–720,000 lives saved since 1895.

    How this number was built

    No published total; a floor for two places. Germany: over 50,000 children died of diphtheria a year before serum (NobelPrize.org, s22), held flat. US: 100,000-200,000 cases a year in the 1920s (CDC, s21). Effect: in Fibiger's 1898 trial 8 of 239 serum-treated vs 30 of 245 controls died (3.3% vs 12.2%: 73% fewer, 8.9 points; s20). Germany 1895-1914: 50,000 x 30-73% fewer deaths x 50-80% treated x 20 yrs = 150,000-584,000. US 1920-29: 1.0-2.0M cases x 50-80% treated x 8.9 points = 44,500-142,000. Total 194,500-726,000, rounded down. The 30% low is under Fibiger's 95% lower bound (42%) as Danish 1894-95 trials found no benefit (s23); treated shares only cut the totals. Other places and years excluded. Share 0.08: Behring and Kitasato found antitoxin, Roux proved it in children; Ehrlich's concentration and standard unit made doses reliable (s22, s9).[9],[10],[20],[21],[22],[23]

    Sources: BMJ, via PubMed Central; US Centers for Disease Control and Prevention; NobelPrize.org (Nobel Prize Outreach); The James Lind Library; Paul-Ehrlich-Institut; Paul-Ehrlich-Institut

  • Low confidenceRippleModeledHealth

    TB deaths averted by treatment, credited via the acid-fast stain used to find patients

    225,000–372,000

    lives saved, credited share

    That is 0.3% of 75–124 million lives saved since 1946.

    How this number was built

    Same outcome and range as the Waksman profile: WHO says TB efforts saved 83M lives in 2000-2024 (s26, s27) against a 43% untreated case-fatality rate (s28). Low: 83M minus ~8M for HIV drugs = 75M. High adds 2025 (3.3M), the 1990s (7.8M, Dolin s29) and 1947-1989 (~30M) = ~124M. Link: treatment needs a diagnosis, and acid-fast smear microscopy 'remains the cornerstone' of TB diagnosis in low- and middle-income countries, where over 90% of cases occur (Vilcheze and Kremer, s24). In 1882 Ehrlich replaced Koch's methylene blue with fuchsin or methyl violet in aniline water; Ziehl (Aug 1882) and Neelsen (1883) refined it into the stain still used. Share 0.003: diagnosis gets ~0.1 of the credit (drugs, programmes, X-ray and culture the rest), Ehrlich ~0.2 of the stain's, cut to ~0.15 because Ziehl's version followed within months: 0.1 x 0.2 x 0.15 = 0.003. Waksman 0.05; total 0.053.[24],[25],[26],[27],[28]

    Sources: Microbiology Spectrum (ASM), via PubMed Central; World Health Organization; World Health Organization; World Health Organization; Bulletin of the World Health Organization, via PubMed

The double edge

Salvarsan was a huge advance, but it was far from harmless. It contained arsenic, was hard to prepare and inject correctly, and could cause rashes, liver damage and sometimes death, especially when doctors mixed or dosed it badly. Treatment meant repeated injections over a year or more, and many patients gave up partway. Deaths among early test patients led critics to call Ehrlich reckless and greedy; a newspaper's claim that a Frankfurt hospital forced prostitutes to take the drug ended in a 1914 libel conviction. In October 1914 Ehrlich also signed the Manifesto of the Ninety-Three, in which prominent German scientists, scholars and artists denied their country's guilt for the war and for atrocities against Belgian civilians.

  • Moderate

    An arsenic drug with serious side effects

    Salvarsan is an arsenic compound. It had to be dissolved and injected with great care, and side effects included rashes, liver damage and, occasionally, death; many injuries came from doctors who prepared or dosed it badly. A US syphilis expert later recalled that before penicillin, heavy-metal treatments for syphilis, arsenic among them, often caused thousands of deaths a year.[5],[13],[14]

  • Minor

    A long, hard treatment that many abandoned

    Arsenic treatment for syphilis meant a year or more of repeated injections, usually combined with bismuth; one review describes a minimum course of about 18 months with 20 arsenic and 30-40 bismuth injections. Success rates above 90% were reported for early syphilis in patients who finished, but perhaps only a quarter did, leaving many partly treated.[6],[14],[16]

  • Moderate

    Deaths in testing and the 'Salvarsan war'

    Deaths among early test patients led critics to accuse Ehrlich of recklessness and of getting rich from the drug. A Frankfurt newspaper claimed prostitutes were being forced to take it; in 1914 the publisher was convicted of libel and jailed for a year. Some of the attacks carried antisemitic undertones.[5],[12],[13]

  • Minor

    Signed a wartime manifesto

    In October 1914 Ehrlich was one of 93 prominent Germans who signed a manifesto 'to the civilized world' denying that Germany had caused the war or committed atrocities in Belgium, and defending German militarism.[12],[19]

Against the odds

Ehrlich lived and worked in Prussia, part of the German Empire from 1871, and his path to the top was neither smooth nor secure. After his supportive chief at Berlin's Charité hospital died in 1885, the new head impeded his research. After recovering from tuberculosis, he worked at Robert Koch's institute for more than three years without a salary. He was 60 before he held a regular university chair, at Frankfurt's new university in 1914. Part of the reason was his unusual blend of chemistry and medicine, which fit no existing department, but a 2008 centenary review by Bosch and Rosich concluded that, because his parents were Jewish, he never got the recognition in Germany that his work deserved, in life or after death. When Salvarsan made him famous, critics accused him of greed and reckless experiments, with antisemitic undertones, and the strain of a 1914 libel trial sent him into a depression. He died in 1915, but the Nazis later tried to erase him. Frankfurt's Paul-Ehrlich-Strasse was renamed because he was Jewish, a scientist appointed to his former institute in 1935 had all his writings removed from its library, and his portrait was slashed during the Kristallnacht pogrom of 1938. His widow and daughters were persecuted as Jews and fled Germany. His son-in-law, the mathematician Edmund Landau, was pushed out of his Göttingen professorship after a student boycott of his lectures in 1933.

  • —

    Discrimination

    Despite many honours, a 2008 centenary review by Bosch and Rosich concluded that, because his parents were Jewish, the recognition Ehrlich received in Germany, in life and after death, never matched his achievements. He did not hold a regular university chair until 1914, at age 60.[5],[6],[12]

  • 1914

    Antisemitic attack

    In the 'Salvarsan war', opponents accused Ehrlich of greed and dangerous experiments, with antisemitic undertones. A Frankfurt newspaper's campaign ended in a 1914 libel trial in which Ehrlich testified; the publisher was jailed, but the strain sent Ehrlich into a depression.[5],[12]

  • 1935

    Persecution

    After his death the Nazis worked to erase his memory. Frankfurt's Paul-Ehrlich-Strasse was renamed because he was Jewish, a scientist appointed to his former institute in 1935 had all his writings removed from its library, and his portrait was slashed on Kristallnacht in 1938.[2],[9],[12]

  • —

    Exile

    Under the Nazis, Ehrlich's widow Hedwig and their daughters were persecuted as Jews and fled Germany.[5]

  • 1933

    Dismissal

    His daughter Marianne's husband, the Jewish mathematician Edmund Landau, was forced out of his Göttingen professorship after a student boycott of his lectures in November 1933, believed to have been organized by Nazi stormtroopers.[2],[17]

Jewish background

Both parents JewishIdentified as Jewish, secular

Ehrlich was born in Strehlen, Silesia, to Jewish parents. His father Ismar, a distiller and innkeeper, led the town's Jewish community, and his mother Rosa came from the Weigert family, which also produced the pathologist Carl Weigert. In 1883 he married Hedwig Pinkus, from a textile-manufacturing family, in the synagogue at Neustadt, and in 1915 he was buried in Frankfurt's Jewish cemetery. The Encyclopaedia Judaica says Jewish affairs interested him throughout his life: he was an active member of the society Le-Ma'an Zion and supported the Nordau Institute, one of the seeds of the Hebrew University of Jerusalem.[5],[6],[12]

Key dates

  1. March 14, 1854

    Born in Strehlen, Prussian Silesia (now Strzelin, Poland), the only son of a Jewish distiller and innkeeper.[1],[5]

  2. 1878

    Earns his medical doctorate at Leipzig with a thesis on staining tissues with dyes, then joins Friedrich von Frerichs' clinic at the Charité in Berlin.[2],[5]

  3. April 14, 1883

    Marries Hedwig Pinkus in the synagogue at Neustadt, Upper Silesia; they have two daughters, Stephanie and Marianne.[5],[12]

  4. 1891

    Joins Robert Koch's new Institute for Infectious Diseases in Berlin, working unpaid for over three years on immunity.[5],[12]

  5. 1896

    Becomes director of the new Institute for Serum Research and Testing at Steglitz, the forerunner of today's Paul-Ehrlich-Institut.[2],[9],[10]

  6. 1897

    Publishes his method for measuring diphtheria antitoxin against a fixed standard unit, groundwork for his side-chain theory of antibodies.[2],[5]

  7. 1899

    Moves to Frankfurt as director of the Royal Prussian Institute for Experimental Therapy.[2],[5]

  8. 1906

    Opens the Georg-Speyer-Haus for chemotherapy research and describes his goal of 'magic bullets'.[5],[8]

  9. 1908

    Shares the Nobel Prize in Physiology or Medicine with Ilya Mechnikov 'in recognition of their work on immunity'.[1],[2],[4]

  10. 1909

    Sahachiro Hata finds that compound 606, set aside in 1907 as ineffective, cures syphilis in rabbits.[2],[7]

  11. 1910

    Announces the first results in April; by year's end Hoechst is making the drug, sold as Salvarsan.[5],[7]

  12. 1914

    Testifies at a libel trial over false claims about Salvarsan; becomes a full professor at Frankfurt's new university.[5],[12]

  13. August 20, 1915

    Dies after a second stroke in Bad Homburg; he is buried in Frankfurt's Jewish cemetery.[1],[2],[5]

  14. 1935

    Richard Otto, newly appointed to Ehrlich's former institute, has all of Ehrlich's writings removed from its library.[9]

Sources

  1. 1.Paul Ehrlich - Facts · NobelPrize.org (Nobel Prize Outreach)
  2. 2.Paul Ehrlich - Biographical · NobelPrize.org (from Nobel Lectures, Physiology or Medicine 1901-1921, Elsevier, 1967), 1967
  3. 3.Partial Cell Functions (Nobel Lecture, 11 December 1908) · NobelPrize.org, 1908
  4. 4.The Nobel Prize in Physiology or Medicine 1908 - Presentation Speech by Count K.A.H. Mörner · NobelPrize.org, 1908
  5. 5.Ehrlich, Paul (entries from the Complete Dictionary of Scientific Biography by Claude E. Dolman, Encyclopaedia Judaica by Aryeh Leo Olitzki, World of Microbiology and Immunology, and Encyclopedia of Modern Europe) · Encyclopedia.com (Gale)
  6. 6.The Contributions of Paul Ehrlich to Pharmacology: A Tribute on the Occasion of the Centenary of His Nobel Prize, by F. Bosch and L. Rosich (Pharmacology 82: 171-179) · Karger, via PubMed Central, 2008
  7. 7.The introduction of 'chemotherapy' using arsphenamine - the first magic bullet, by K.J. Williams (J R Soc Med 102: 343-348) · James Lind Library, 2009
  8. 8.Paul Ehrlich · Science History Institute
  9. 9.History of the Paul-Ehrlich-Institut · Paul-Ehrlich-Institut
  10. 10.Paul Ehrlich - Immunologist, Scientist and Nobel Laureate · Paul-Ehrlich-Institut
  11. 11.Salvarsan (The Top Pharmaceuticals That Changed the World) · Chemical & Engineering News (American Chemical Society), 2005
  12. 12.Paul Ehrlich · Wikipedia
  13. 13.The Salvarsan Wars · Proto Magazine (Massachusetts General Hospital), 2010
  14. 14.Syphilis - Its Early History and Treatment until Penicillin and the Debate on its Origins, by John Frith (Journal of Military and Veterans' Health 20(4)) · Journal of Military and Veterans' Health, 2012
  15. 15.Syphilis 100 years later: Another lost opportunity?, by Kristin A. Englund (Cleveland Clinic Journal of Medicine 84(7): 514) · Cleveland Clinic Journal of Medicine, 2017
  16. 16.Penicillin and historic syphilis trends (summarizing R.R. Willcox, British Journal of Venereal Diseases, 1962) · AI Impacts
  17. 17.Edmund Georg Hermann Landau (biography) · MacTutor History of Mathematics, University of St Andrews
  18. 18.A 20th Century Historical Perspective on Congenital Syphilis and Lessons for Today, by J.F. Knapp and R.D. Schremmer (Missouri Medicine 123(1): 15) · Missouri State Medical Association, via PubMed Central, 2026
  19. 19.Manifesto of the Ninety-Three · Wikipedia
  20. 20.The controlled clinical trial turns 100 years: Fibiger's trial of serum treatment of diphtheria (Hrobjartsson A, Gotzsche PC, Gluud C, BMJ 317:1243-1245) · BMJ, via PubMed Central, 1998
  21. 21.Diphtheria (Epidemiology and Prevention of Vaccine-Preventable Diseases, the Pink Book, chapter 7) · US Centers for Disease Control and Prevention, 2024
  22. 22.Emil von Behring: The founder of serum therapy · NobelPrize.org (Nobel Prize Outreach)
  23. 23.Danish contributions to the evaluation of serum therapy for diphtheria in the 1890s (Gluud C) · The James Lind Library, 2010
  24. 24.Acid-Fast Positive and Acid-Fast Negative Mycobacterium tuberculosis: The Koch Paradox (Vilcheze C, Kremer L, Microbiology Spectrum 5(2)) · Microbiology Spectrum (ASM), via PubMed Central, 2017
  25. 25.Tuberculosis (fact sheet) · World Health Organization, 2026
  26. 26.Global tuberculosis report 2025: fact sheet · World Health Organization, 2025
  27. 27.Technical appendix: methods used by WHO to estimate the global burden of TB (Global tuberculosis report 2024) · World Health Organization, 2024
  28. 28.Global tuberculosis incidence and mortality during 1990-2000 (Dolin P.J., Raviglione M.C., Kochi A., Bull World Health Organ 72:213-220) · Bulletin of the World Health Organization, via PubMed, 1994

Fact-checked on September 24, 2026 by a separate AI fact-checking pass that re-opened the sources, with 13 corrections made. How we check

Suggest a correction